Martin Dunbar Selected Research

Platinum

11/2021	Veliparib in Combination With Platinum-Based Chemotherapy for First-Line Treatment of Advanced Squamous Cell Lung Cancer: A Randomized, Multicenter Phase III Study.
11/2021	Veliparib and nivolumab in combination with platinum doublet chemotherapy in patients with metastatic or advanced non-small cell lung cancer: A phase 1 dose escalation study.
10/2018	A phase 1 study of PARP-inhibitor ABT-767 in advanced solid tumors with BRCA1/2 mutations and high-grade serous ovarian, fallopian tube, or primary peritoneal cancer.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Martin Dunbar Research Topics

Disease

5	Neoplasms (Cancer) 01/2022 - 04/2015
4	Hematologic Neoplasms (Hematological Malignancy) 01/2017 - 10/2016
3	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 10/2023 - 11/2021
3	Non-Hodgkin Lymphoma (Lymphosarcoma) 03/2017 - 01/2017
3	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 01/2017 - 01/2016
2	Lung Neoplasms (Lung Cancer) 01/2022 - 11/2021
2	Nausea 01/2022 - 04/2015
2	Fatigue 01/2022 - 04/2015
2	Pain (Aches) 11/2020 - 10/2015
2	Infections 01/2018 - 01/2016
2	B-Cell Lymphoma (Lymphoma, B Cell) 01/2018 - 01/2017
2	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 02/2017 - 10/2016
1	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 01/2021
1	Disease Progression 10/2018
1	Respiratory Insufficiency (Respiratory Failure) 01/2018
1	Carcinoma (Carcinomatosis) 01/2018
1	Sepsis (Septicemia) 01/2018
1	Breast Neoplasms (Breast Cancer) 01/2018
1	Multiple Myeloma 11/2017
1	Lymphoma (Lymphomas) 10/2016
1	B-Cell Leukemia (Leukemia, B Cell) 10/2016
1	Drug-Related Side Effects and Adverse Reactions 01/2016
1	Chronic Pain 10/2015
1	Brain Neoplasms (Brain Tumor) 04/2015
1	Hypokalemia 04/2015
1	Hyponatremia 04/2015

Drug/Important Bio-Agent (IBA)

11	venetoclaxIBA 01/2018 - 01/2016
6	veliparibIBA 01/2022 - 04/2015
4	Poly(ADP-ribose) Polymerase InhibitorsIBA 01/2022 - 10/2018
3	Proteins (Proteins, Gene)FDA Link 10/2023 - 01/2017
3	PlatinumIBA 11/2021 - 10/2018
2	Carboplatin (JM8)FDA LinkGeneric 01/2022 - 01/2021
2	Poly(ADP-ribose) Polymerases (Poly ADP Ribose Polymerase)IBA 10/2018 - 01/2018
2	Cytochrome P-450 CYP3A InhibitorsIBA 02/2017 - 01/2017
1	ErbB Receptors (EGF Receptor)IBA 10/2023
1	telisotuzumab vedotinIBA 10/2023
1	Erlotinib Hydrochloride (CP 358,774)FDA Link 10/2023
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2022
1	Alanine Transaminase (SGPT)IBA 01/2022
1	Aspartate Aminotransferases (Aspartate Transaminase)IBA 01/2022
1	Death Domain ReceptorsIBA 01/2022
1	Paclitaxel (Taxol)FDA LinkGeneric 01/2022
1	LigandsIBA 01/2022
1	Biomarkers (Surrogate Marker)IBA 11/2021
1	NivolumabIBA 11/2021
1	Etoposide (VP 16)FDA LinkGeneric 01/2021
1	ABT-767IBA 10/2018
1	Cytochrome P-450 CYP3AIBA 02/2017
1	posaconazole FDA Link 02/2017
1	Antifungal AgentsIBA 02/2017
1	Rilpivirine (TMC-278)IBA 01/2016
1	Antiviral Agents (Antivirals)IBA 01/2016

Therapy/Procedure

4	Drug Therapy (Chemotherapy) 01/2022 - 10/2016
2	Pain Management 11/2020 - 10/2015
2	Therapeutics 11/2017 - 01/2017
1	Radiotherapy 04/2015